On September 15, 2026, Beta Bionics, Inc. entered into an underwriting agreement for a public offering of common stock. The company expects to raise approximately $150 million from the sale of 7,652,175 shares at a price of $17.25 each. Additionally, warrants to purchase shares are included for certain investors
Company Information
Company
Beta Bionics
Location
300 Baker Avenue, Suite 301
Concord, Massachusetts, United States
About
Beta Bionics is a commercial stage medical technology company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWDs) by utilizing advanced adaptive algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared autonomous insulin delivery device in the market and offers the potential to substantially improve overall outcomes across broad populations of PWDs.
Don't miss Beta Bionics's next move
Get an email the moment Beta Bionics raises, hires an exec, or expands, usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
2 contacts
Verified contactsKevin M., Director hidden
Predictive Intelligence
Strategic
ML-powered predictions for Beta Bionics's next move
ConcordBiotechnologyHealthcare